Nadine Mirchandani, a partner in Ernst & Young's transaction advisory services, gives The Deal Pipeline her predictions on the short- and long-term lifespan of financial services M&A. Mirchandani also discusses new opportunities for asset managers, as well as whether she is seeing opportunities for acquirers being created from global economic turmoil. - Sarah Hashim-Waris
Three directors are leaving Valeant Pharmaceuticals International's board, including Warburg Pincus' Fred Hassan, ValueAct's G. Mason Morfit and Persistence Capital's Lloyd M. Segal. For other updates launch today's Movers & shakers slideshow.
The move suggests activism has entered a new phase. But as seen with the Men′s Wearhouse-Jos. A. Bank merger, it′s just another way for dissident investors to push their agendas. More video